

File reference	W17FOI241
Key words	Breast cancer drug treatment
Date of release	07/09/2017
Attachments	Yes

Freedom of Information Act Disclosure log - Reply Extract

You asked

In your trust, how many patients with HER2 breast cancer are currently being treated (in the past 3 months available) with the following products;

Herceptin IV (trastuzumab IV) only

Herceptin SC (trastuzumab SC) only

Perjeta (pertuzumab) combined with Herceptin/Docatexel

Kadcyla (trastuzumab emtansine)

Tyverb (lapatinib)

Our reply

This response includes patients treated between 1/5/17 – 31/7/17

Medicines/combinations	Number of patients
Herceptin IV (trastuzumab IV) only	10
Herceptin SC (trastuzumab SC) only	49
Perjeta (pertuzumab) combined with Herceptin/Docatexel	Five or fewer
Kadcyla (trastuzumab emtansine)	6
Tyverb (lapatinib)	0

Plymouth Hospitals NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles. This is in accordance with section 40.-(2)(a) and (b) by virtue of section 40.-(3)(a)(i), the personal information exemption as described in the Freedom of Information Act. A detailed rationale is provided in the attached document L3.